BACKGROUND: We confirmed the benefit of addition of ixazomib to lenalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM) in unselected real-world population. We report the final analysis for overall survival (OS), second progression free survival (PFS-2), and the subanalysis of the outcomes in lenalidomide (LEN) pretreated and LEN refractory patients. METHODS: We assessed 344 patients with RRMM, treated with IRD (N = 127) or RD (N = 217). The data were acquired from the Czech Registry of Monoclonal Gammopathies (RMG). With prolonged follow-up (median 28.5 months), we determined the new primary endpoints OS, PFS and PFS-2. Secondary endpoints included the next therapeutic approach and the survival measures in LEN pretreated and LEN refractory patients. RESULTS: The final overall response rate (ORR) was 73.0% in the IRD cohort and 66.8% in the RD cohort. The difference in patients reaching ≥VGPR remained significant (38.1% vs. 26.3%, p = 0.028). Median PFS maintained significant improvement in the IRD cohort (17.5 vs. 12.5 months, p = 0.013) with better outcomes in patients with 1-3 prior relapses (22.3 vs. 12.7 months p = 0.003). In the whole cohort, median OS was for IRD vs. RD patients 40.9 vs. 27.1 months (p = 0.001), with further improvement within relapse 1-3 (51.7 vs. 27.8 months, p ˂ 0.001). The median PFS of LEN pretreated (N = 22) vs. LEN naive (N = 105) patients treated by IRD was 8.7 vs. 23.1 months (p = 0.001), and median OS was 13.2 vs. 51.7 months (p = 0.030). Most patients in both arms progressed and received further myeloma-specific therapy (63.0% in the IRD group and 53.9% in the RD group). Majority of patients received pomalidomide-based therapy or bortezomib based therapy. Significantly more patients with previous IRD vs. RD received subsequent monoclonal antibodies (daratumumab-16.3% vs. 4.3%, p = 0.0054; isatuximab 5.0% vs. 0.0%, p = 0.026) and carfilzomib (12.5 vs. 1.7%, p = 0.004). The median PFS-2 (progression free survival from the start of IRD/RD therapy until the second disease progression or death) was significantly longer in the IRD cohort (29.8 vs. 21.6 months, p = 0.016). There were no additional safety concerns in the extended follow-up. CONCLUSIONS: The IRD regimen is well tolerated, easy to administer, and with very good therapeutic outcomes. The survival measures in unsorted real-world population are comparable to the outcomes of the clinical trial. As expected, patients with LEN reatment have poorer outcomes than those who are LEN-naive. The PFS benefit of IRD vs. RD translated into significantly better PFS-2 and OS, but the outcomes must be accounted for imbalances in pretreatment group characteristics (especially younger age and stem cell transplant pretreatment), and in subsequent therapies.

1st Medical Department Clinical Department of Haematology 1st Faculty of Medicine and General Teaching Hospital Charles University 110 00 Prague Czech Republic

4th Department of Internal Medicine Hematology Faculty Hospital Charles University in Hradec Kralove 500 03 Hradec Kralove Czech Republic

Department of Hemato Oncology Faculty of Medicine and Dentistry Palacky University Olomouc and University Hospital Olomouc 779 00 Olomouc Czech Republic

Department of Hematology and Transfusiology University Hospital Faculty of Medicine Slovak Medical University and Comenius University 831 01 Bratislava Slovakia

Department of Hematooncology University Hospital Ostrava Faculty of Medicine University of Ostrava 708 00 Ostrava Czech Republic

Department of Internal Medicine and Hematology 3rd Faculty of Medicine Charles University and Faculty Hospital Kralovske Vinohrady 100 34 Prague Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Hematology and Oncology Department Charles University Hospital Pilsen 323 00 Pilsen Czech Republic

Institute of Biostatistics and Analyses Ltd 602 00 Brno Czech Republic

Zobrazit více v PubMed

Moreau P., Masszi T., Grzasko N., Bahlis N.J., Hansson M., Pour L., Sandhu I., Ganly P., Baker B.W., Jackskon S.R., et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016;374:1621–1634. doi: 10.1056/NEJMoa1516282. PubMed DOI

Minarik J., Pika T., Radocha J., Jungova A., Straub J., Jelinek T., Pour L., Pavlicek P., Mistrik M., Brozova L., et al. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer. 2021;21:73. doi: 10.1186/s12885-020-07732-1. PubMed DOI PMC

Rajkumar S.V., Harousseau J.L., Durie B., Anderson K.C., Dimopoulos M., Kyle R., Blade J., Richardson P., Orlowski R., Siegel D., et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the international myeloma workshop consensus panel 1. Blood. 2011;117:4691–4695. doi: 10.1182/blood-2010-10-299487. PubMed DOI PMC

Durie B.G., Harousseau J.L., Miguel J.S., Blade J., Barlogie B., Anderson K., Gertz M., Dimopoulos M., Westin J., Sonneveld P., et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473. doi: 10.1038/sj.leu.2404284. PubMed DOI

Blade J., Samson D., Reece D., Apperley J., Bjorkstrand B., Gahrton G., Gertz M., Giralt S., Jagannath S., Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 1998;102:1115–1123. doi: 10.1046/j.1365-2141.1998.00930.x. PubMed DOI

Software R Version 3.4.2. [(accessed on 3 June 2021)]. Available online: http://www.r-project.org.

Costello C., Davies F.E., Cook G., Vela-Ojeda J., Omel J., Rifkin R.M., Berdeja J., Puig N., Usmani S.Z., Weisel K., et al. INSIGHT MM: A large, global, prospective, non-Interventional, real-world study of patients with multiple myeloma. Future Oncol. 2019;15:1411–1428. doi: 10.2217/fon-2019-0013. PubMed DOI PMC

Shah J.J., Abonour R., Gasparetto C., Hardin J.W., Toomey K., Narang M., Srinivasan S., Kitali A., Zafar F., Flick E.D., et al. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clin. Lymhopma Myeloma Leuk. 2017;17:575–583. doi: 10.1016/j.clml.2017.06.013. PubMed DOI

Hungria V.T.M., Lee H.C., Abonour R., Rifkin R.M., Terpos E., Leleu X., Costello C.L., van Rhee F., Weisel K., Puig N., et al. Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3000 Pts from the Insight MM Global, Prospective, Observational Study. Blood. 2019;134((Suppl. S1)):1887. doi: 10.1182/blood-2019-125749. PubMed DOI

Chari A., Richardson P.G., Romanus D., Dimopoulos M.A., Sonneveld P., Terpos E., Hajek R., Raju A., Palumbo A., Cain L.E., et al. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): A comparison of VRd, KRd, and IRd. Expert Rev. Hematol. 2020;13:421–433. doi: 10.1080/17474086.2020.1729734. PubMed DOI

Richardson P.G., San Miguel J.F., Moreau P., Hajek R., Dimopoulos M.A., Laubach J.P., Palumbo A., Luptakova K., Romanus D., Skacel T., et al. Interpreting clinical trial data in multiple myeloma: Translating findings to the real-World setting. Blood Cancer J. 2018;8:109. doi: 10.1038/s41408-018-0141-0. PubMed DOI PMC

Costa L.J., Hari P.N., Kumar S.K. Differences between unselected patients and participants in multiple myeloma clinical trials in US: A threat to external validity. Leuk Lymphoma. 2016;57:2827–2832. doi: 10.3109/10428194.2016.1170828. PubMed DOI

FDA Framework for FDA’s Real-World Evidence Program, 2018. [(accessed on 3 June 2021)]; Available online: http://www.fda.gov.

Blonde L., Khunti K., Harris S.B., Meizinger C., Skolnik N.S. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv. Ther. 2018;35:1763–1774. doi: 10.1007/s12325-018-0805-y. PubMed DOI PMC

Makady A., de Boer A., Hillege H., Klungel O., Goettsch W. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews. Value Health. 2017;20:858–865. doi: 10.1016/j.jval.2017.03.008. PubMed DOI

RMG Registry. [(accessed on 6 April 2022)]. Available online: https://rmg.healthregistry.org/

Richardson P.G., Kumar S.K., Masszi T., Grzasko N., Bahlis N.J., Hansson M., Pour L., Sandhu I., Ganly P., Baker B.W., et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J. Clin. Oncol. 2021;39:2430–2443. doi: 10.1200/JCO.21.00972. PubMed DOI

Hou J., Jin J., Xu Y., Wu D., Ke X., Zhou D., Lu J., Du X., Chen X., Li J., et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J. Hematol. Oncol. 2017;10:137. doi: 10.1186/s13045-017-0501-4. PubMed DOI PMC

Hajek R., Minarik J., Straub J., Pour L., Jungova A., Berdeja J.G., Boccadoro M., Brozova L., Spencer A., van Rhee F., et al. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021;17:2499–2512. doi: 10.2217/fon-2020-1225. PubMed DOI

Terpos E., Ramasamy K., Maouche N., Minarik J., Ntanasis-Stathopoulos I., Katodritou E., Jenner M.W., Plonkova H., Gavriatopoulou M., Vallance G.D., et al. Real-World effectiveness and safety of ixazomib-lenalidomide-Dexamethasone in relapsed/refractory multiple myeloma. Ann. Hematol. 2020;99:1049–1061. doi: 10.1007/s00277-020-03981-z. PubMed DOI

Cohen Y.C., Magen H., Lavi N., Gatt M.E., Chubar E., Norowitz N., Kreiniz N., Tadmor T., Trestmen S., Vitkon R., et al. Ixazomib-based regimens for relapsed/refractory multiple myeloma: Are real-World data compatible with clinical trial outcomes? A multi-Site Israeli registry study. Ann. Hematol. 2020;99:1273–1281. doi: 10.1007/s00277-020-03985-9. PubMed DOI

Ziff M., Lawson G., De-Silva D., Cheesman S., Kyriakou C., Mahmood S., Papanikolaou X., Rabin N., Sachchithananthan S., Sive J., et al. Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: Impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leuk Lymphoma. 2021;62:1243–1246. doi: 10.1080/10428194.2020.1864356. PubMed DOI

Ludwig H., Terpos E., Mateos M.V., Boccadoro M., Kishore B., Ramasamy K., Fernandez S., Ferri F., Bent-Ennakhil N., Zomas A., et al. Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study. Blood. 2020;136((Suppl. S1)):42–44.

Reece D.E., Masih-Khan E., Atenafu E.G., Jimenez-Zepeda V., McCurdy A., Song K., Sebag M., Leblanc R., Louzada M.L., White D.J., et al. Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens. Bood. 2019;134((Suppl. S1)):1886. doi: 10.1182/blood-2019-125479. DOI

Varga G., Nagy Z., Demeter J., Kosztolányi S., Szomor A., Alizadeh H., Deák B., Schneider T., Plander M., Szendrei T., et al. Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program. Pathol. Oncol. Res. 2019;25:1615–1620. doi: 10.1007/s12253-019-00607-2. PubMed DOI PMC

Li J., Bao L., Xia Z., Ding K., Li B., Chen B., Fu Z., Wang S., Zhang W., Zhou X., et al. The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China. Blood. 2019;134((Suppl. S1)):5592. doi: 10.1182/blood-2019-130040. DOI

Takakuwa T., Yamamura R., Ohta K., Kaneko H., Imada K., Nakaya A., Fuchida S.-I., Shibayama H., Matsuda M., Shimazu Y., et al. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. Eur. J. Haematol. 2021;106:555–562. doi: 10.1111/ejh.13586. PubMed DOI

Sokol J., Guman T., Chudej J., Hlebaskova M., Stecova N., Valekova L., Kucerikova M., Stasko J. Ixazomib, lenalidomide and dexamethasone combination in “real-world” clinical practice in patients with relapsed/refractory multiple myeloma. Ann. Hematol. 2022;101:81–89. doi: 10.1007/s00277-021-04663-0. PubMed DOI

Minarik J., Krhovska P., Jelinek T., Jungova A., Mistrik M., Pika T., Gregora E., Maisnar V., Straub J., Pour L., et al. Treatment of relapsed and refractory multiple myeloma with fully oral triplet IRD (ixazomib, lenalidomide and dexamethasone) is safe and with significant therapeutic outcomes. Blood. 2018;132((Suppl. S1)):1959. doi: 10.1182/blood-2018-99-112046. DOI

Minarik J., Pika T., Radocha J., Jungova A., Straub J., Jelinek T., Pour L., Pavlicek P., Mistrik M., Brozova L., et al. Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG) Blood. 2019;134((Suppl. S1)):3139. doi: 10.1182/blood-2019-128865. DOI

Minarik J., Radocha J., Jungova A., Straub J., Jelinek T., Pika T., Pour L., Pavlicek P., Harvanova L., Capkova L., et al. Follow-up analysis of ixazomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in routine clinical practice. Blood. 2021;138((Suppl. S1)):2716. doi: 10.1182/blood-2021-148836. DOI